Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brimonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 20/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 19/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 19/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 14/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 11/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 12/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | HTR1A | P08908 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brimonidine SCHEMBL27455839 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29377437 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29356891 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29470063 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL34647 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29378438 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL34649 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL22616168 | 0.99 | ADRA2A (0.98) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL22616169 | 0.99 | ADRA2A (0.98) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29227701 | 0.99 | ADRA2A (0.98) | ADRA2AADRA2BADRA2CADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000644-A1 | Biocompatible Biodegradable Intraocular Implant System | INSIGHT INNOVATIONS, LLC (US) | 2017-01-05 | — | — | US | claimed |
| US-20110230963-A1 | BIOCOMPATIBLE BIODEGRADABLE INTRAOCULAR IMPLANT SYSTEM | INSIGHT INNOVATIONS, LLC | 2011-09-22 | — | — | US | claimed |
| EP-2364127-A2 | BIOCOMPATIBLE BIODEGRADABLE INTRAOCULAR IMPLANT SYSTEM | Insight Innovations, Llc (US) | 2011-09-14 | — | — | EP | claimed |
| WO-2010059214-A2 | BIOCOMPATIBLE BIODEGRADABLE INTRAOCULAR IMPLANT SYSTEM | INSIGHT INNOVATIONS, LLC (US) | 2010-05-27 | — | — | WO | claimed |
| WO-2023202705-A1 | OPHTHALMIC PREPARATION AND APPLICATION THEREOF IN TREATING PRESBYOPIA | 温州医科大学附属眼视光医院 | 2023-10-26 | — | — | WO | disclosed |
| US-20230218627-A1 | PRESERVATIVE FREE PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC ADMINISTRATION COMPRISING BRIMONIDINE | PHARMATHEN S.A. (GR) | 2023-07-13 | — | — | US | disclosed |
| CN-114195724-A | Preparation method of brimonidine tartrate impurity E | 深圳市祥根生物医药有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3231429-B1 | AQUEOUS COMPOSITION COMPRISING BRIMONIDINE AND RIPASUDIL | KOWA CO (JP) | 2021-03-17 | — | — | EP | disclosed |
| US-10220043-B2 | Aqueous composition | KOWA COMPANY, LTD. (JP) | 2019-03-05 | — | — | US | disclosed |
| US-20170360799-A1 | AQUEOUS COMPOSITION | KOWA COMPANY, LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
| EP-3231429-A1 | NOVEL AQUEOUS COMPOSITION | Kowa Company, Ltd. (JP) | 2017-10-18 | — | — | EP | disclosed |
| EP-3127509-A1 | BIOCOMPATIBLE BIODEGRADABLE INTRAOCULAR IMPLANT SYSTEM | Insight Innovations, Llc (US) | 2017-02-08 | — | — | EP | disclosed |
| US-8403176-B2 | Controlled drop dispensing container | ALLERGAN, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2004064756-A2 | CONTROLLED DROP DISPENSING CONTAINER | ALLERGAN, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040140319-A1 | Controlled drop dispensing container | ALLERGAN, INC. | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10220043-B2 | Aqueous composition | GNAQ, BRI3BP, SFPQ | ADRA2A 210/4885ADRA2B 160/4885ADRA2C 72/4885 |
| US-20170360799-A1 | AQUEOUS COMPOSITION | GNAQ, BRI3BP, SFPQ | ADRA2A 210/4885ADRA2B 160/4885ADRA2C 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.